[Consensus on the diagnosis and treatment of pituitary prolactinoma (2025 edition)]

Pituitary prolactinoma, the most prevalent functional pituitary adenomas, has witnessed significant advancements in diagnostic and therapeutic concepts with the advancement of surgical techniques and the update of more clinical evidence-based medical evidence. Based on the 2014 version of the "Chinese Consensus on the Diagnosis and Treatment of Pituitary Prolactin Adenoma", the China Pituitary Adenoma Specialist Council has revised this consensus, in accordance with the latest evidence-based medical evidence and clinical experience, aiming to provide standardized diagnosis and treatment suggestions for clinicians. The consensus systematically expounds the epidemiological characteristics, clinical manifestations, diagnostic criteria, differential diagnosis process and treatment strategies of prolactinomas, and puts forward individualized management suggestions for special populations (such as pregnant women, male patients and refractory prolactinomas). The treatment decision strongly advocates for multidisciplinary team evaluation involving specialists from neurosurgery, endocrinology, radiology, radiation oncology, pathology, ophthalmology, and obstetrics/gynecology, etc. Through the raising of recommendation questions, summary and evaluation of evidence, formation of recommendation opinions, expert discussions, and in combination with clinical practice, 36 recommendations have been formed in aspects such as screening, assessment, diagnosis, treatment, and monitoring. This consensus takes into account both clinical needs and international evidence-based standards, providing a highly reliable reference for diagnosis and treatment, and is expected to enhance the standardization and overall level of prolactinoma diagnosis and treatment in China.